Vertex insider plans sale of 266 VRTX shares

Vertex Pharmaceuticals has an insider planning a modest stock sale.

Rhea-AI Filing Summary

Vertex Pharmaceuticals has an insider planning a modest stock sale. A person associated with Vertex intends to sell 266 shares of common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of 133000.00, around 02/13/2026.

The 266 shares were acquired on 05/01/2024 through restricted stock vesting as compensation from the issuer. Vertex had 253,718,831 shares of common stock outstanding, which is a baseline figure for the company’s total share count.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the latest Form 144 for VRTX disclose?

The notice discloses that an insider related to Vertex Pharmaceuticals plans to sell 266 shares of common stock. The sale is expected to occur on or about 02/13/2026 through Fidelity on the NASDAQ exchange.

How many Vertex (VRTX) shares are planned to be sold under this Form 144?

The Form 144 shows a planned sale of 266 shares of Vertex common stock. The aggregate market value listed for this block is 133000.00, indicating a relatively small transaction compared with the company’s total outstanding shares.

How were the VRTX shares in this Form 144 originally acquired?

The 266 Vertex shares were acquired on 05/01/2024 through restricted stock vesting. The filing states they were received from the issuer as compensation, rather than purchased for cash in the open market.

What is the aggregate market value of the VRTX shares to be sold?

The Form 144 lists an aggregate market value of 133000.00 for the 266 Vertex shares. This value reflects the estimated total dollar amount of the planned sale through Fidelity Brokerage Services on the NASDAQ exchange.

How many Vertex (VRTX) shares are outstanding in this Form 144?

The filing reports 253,718,831 shares of Vertex common stock outstanding. This figure provides context for the company’s total share base and helps investors gauge the relative size of the planned 266-share sale.

What type of transaction is reported for the VRTX shares in this Form 144?

The transaction involves restricted stock vesting that occurred on 05/01/2024, classified as compensation from the issuer. The Form 144 then covers the proposed resale of those vested shares through a broker on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 02:54 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001643921
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Bhatia Sangeeta N.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	266	133000.00	253718831	02/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/01/2024	Restricted Stock Vesting	Issuer			266	05/01/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	02/13/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/27/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Sangeeta N. Bhatia
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)